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ABSTRACT Adverse experience during the early postnatal period induces negative alterations in physiological 
and neurobiological functions, resulting in long-term disorder in animal behavior. The aim of the present work 
was to study the long-lasting effects of chronic neonatal stress in white rats and to estimate the possibility of 
their correction using Semax, an analogue of ACTH fragment (4–10). Early neonatal isolation was used as a 
model of early-life stress. Rat pups were separated from their mothers and littermates for 5 h daily during post-
natal days 1–14. The pups of the control group were left undisturbed with the dams. Half of the rats subjected 
to neonatal isolation received an intranasal injection of Semax at a dose of 50 µg/kg daily, from postnatal day 
15 until day 28. The other animals received intranasal vehicle injections daily at the same time points. It was 
shown that neonatal isolation leads to a delay in physical development, metabolic disturbances, and a decrease 
in the corticosterone stress response in white rats. These changes were observed during the first two months of 
life. Semax administration weakened the influence of neonatal isolation on the animals, body weight , reduced 
metabolic dysfunction, and led to an increase in stress-induced corticosterone release to the control values. So 
the chronic intranasal administration of Semax after termination of the neonatal isolation procedure diminishes 
the negative effects of neonatal stress.
KEYWORDS chronic stress; neonatal isolation; Semax; body weight; corticosterone; rat.
ABBREVIATIONS ACTH  adrenocorticotropic hormone; MD – maternal deprivation; NI – neonatal isolation.
INTRODUCTION
It is well known that the neonatal period  of life is very 
important in the neurophysiological mechanisms devel-
opment and the subsequent formation of mental func-
tions. Aversive experience during the early postnatal 
period of human life (such as parental loss, abuse or pa-
rental neglect) results in an increase of psychopathol-
ogy development probability in adulthood [1]. children 
who had severe diseases in the neonatal period are ex-
posed to painful and stressful influences, resulting in 
acute changes and permanent alterations in the struc-
ture and functions of the central nervous system [2]. 
Although the correlation between neonatal stress and 
behavioral disorders in adults has been demonstrated 
by a number of researchers, more study of the question 
are required. Animal experiments using various aver-
sive actions enable to determine the relationship be-
tween the delayed changes in behavior, duration, and 
the type of actions, as well as to facilitate the search for 
methods for correcting the effects of neonatal stress. 
It has been demonstrated in numerous clinical stud-
ies that a disturbance of the socio-emotional moth-
er-infant relationship during the first year of life is a 
significant stressor, which subsequently increases the 
risk of a number of mental disorders development [1, 
3]. Long-term maternal isolation in the early postnatal 
period (neonatal maternal deprivation) also influences   
the behavior and physical development of various ani-
mal species.
there are a lot of studies devoted to the investigation 
of the long-lasting effects of neonatal maternal depri-
vation (MD). It has been demonstrated that the delayed 
effects of chronic MD depend on the duration of the 
daily deprivation of pups. Short-term chronic depriva-
tion (15 min per day during the first 1–2 weeks of life) 
has a positive effect on the subsequent development of 
the animals. the rats that underwent such experience 
showed reduced anxiety and increased exploratory ac-
tivity, as well as learning ability improvement [4–6]. 
Long-term separation of the rat pups from their moth-reSeArcH ArtIcLeS
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er (for 3–6 h per day during the first few weeks of life) 
also causes long-lasting delayed changes in animal be-
havior and is considered to be the neonatal stress model. 
two models of maternal deprivation are used in the ex-
periments. In the first case, the pups of the same litter 
stay together during MD. In the second case, the pups 
are subjected to neonatal isolation (nI): the pups are 
placed into individual boxes, where they are separated 
both from their dams and littermates. An increase in 
the anxiety level and reduced exploratory activity were 
observed in most experiments in the animals subjected 
to MD [7–9]. nevertheless, MD occasionally resulted 
in an increase in the animals exploratory activity [10]. 
the effect of long-term MD on the animals, learning 
ability is also controversial. Different researchers have 
detected both disturbance [11, 12] and improvement 
of the spatial learning ability in maternally deprived 
animals [13]. In some studies, no effect of MD on the 
spatial learning ability of rats was observed [14]. the 
influence of MD and nI on the functioning of the hy-
pothalamic-pituitary-adrenal axis was demonstrated. 
However, the results were appreciably controversial, 
similar to those in the case of the animal behavior al-
teration. thus, whereas some authors reported an in-
crease in stress-induced corticosterone release in mice 
that were subjected to maternal deprivation [15, 16], 
others reported a decrease in this index in animals that 
were subjected to nI [17–19] or MD [20]. In a number of 
studies, no changes in the hormonal stress-response in 
animals that had experienced neonatal stress were re-
vealed [7]. the inconsistency of the results could be due 
to the differences in the experimental protocols and in 
the age of the tested animals [18]. thus development of 
an adequate neonatal stress model in animals and fur-
ther study of the delayed effects of chronic long-term 
maternal deprivation is quite essential.
the heptapeptide Semax (MeHFPGP) is an ActH 
fragment (4–10) analogue that has prolonged neuro-
tropic activity [21]. this peptide possesses neuroprotec-
tive and neurotrophic effects [22, 23]; it also has anti-
hypoxic and antihaemorrhagic action [21, 24]. Semax 
is used in medicine as a nootropic and neuroprotective 
agent [25]. It was demonstrated earlier that chronic ne-
onatal administration of Semax results in enhancement 
of the exploratory behavior and a decrease in anxiety 
in rats. Moreover, the animals that received Semax 
in the neonatal period showed better learning ability 
in subsequent years. these alterations had a delayed 
long-lasting character [26]. Semax neonatal adminis-
tration effects were opposite to the effects of neonatal 
stress: that let us to assume that Semax administration 
can correct the negative effects of neonatal stress. It 
was ascertained in our previous studies that the daily 
neonatal isolation of rat pups for 5 h during 1–2 weeks 
of postnatal development causes long-lasting alteration 
in the animal’s behavior. An increase in anxiety and re-
duction in exploratory activity at the age of 1–2 months 
was observed in rats subjected to nI during the first 
weeks of postnatal development. chronic intranasal 
administration of Semax during 15–28 days of life re-
sulted in a considerable normalization of the emotional 
state of the animals exposed to nI [27].
the aim of the present work is to study the effects 
of neonatal isolation on physical development in rats 
and the hormonal stress-response, as well as to find out 
whether Semax administration during 15-28 postnatal 
days can correct the nI effects.
EXPERIMENTAL
noninbreded white rat pups of both sexes were used. 
the animals were housed in a vivarium under the 
standard conditions with free access to food and water 
and were maintained on a 12 h light–dark cycle. the 
heptapeptide Semax (MeHFPGP) was synthesized in 
the Institute of Molecular Genetics, russian Academy 
of Sciences.
the day of birth of the pups was considered as day 0 
of life. each litter was divided into three groups: the 
control group, the nI group (the animals were sub-
jected to neonatal isolation), and the nI–Semax group 
(the animals were subjected to nI and subsequently re-
ceived Semax). the pups from the control group were 
left undisturbed in their nest for the first two weeks of 
life. the pups from the nI and nI–Semax groups were 
daily placed into individual boxes for 5 h (days 1–14 of 
life). During the isolation, the pups were left in silent 
conditions at a temperature of 25 ± 2°С, and they were 
illuminated with moderate light. the rats from the nI–
Semax group intranasally received a 0.05 mg/kg dose 
of an aqueous Semax solution during the period from 
day 15 to day 28 of life. the pups from the control and 
nI groups received an equivalent volume of the solvent 
during the same time period. During the experiment, 
the age of eye-opening and body weight were recorded 
for each animal (daily during the period from day 15 
to day 28 of life; then, once a week). Blood glucose lev-
els were measured at days 15, 30, and 48 of life. Blood 
samples were obtained from the tip of the tail in order 
to determine the glucose level; the glucose content was 
measured using a glucometer (Accu-chek Performa 
nano).
the level of food motivation in animals was assessed 
on day 42 of life. Prior to the experiment, the animals 
were deprived of food for 20 h. the blood glucose lev-
el was measured in hungry animals; after 30 min had 
elapsed, the rat was placed into an empty cage. After 
5-min adaptation to the new conditions, a weighed por-
tion of food was placed into the cage. then, the follow-88 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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ing parameters were recorded during 10 min: the la-
tency to food intake, feeding duration, and the amount 
of food consumed. next, the rat was placed in a cage 
with unlimited access to food. the glucose level was 
measured again after 30 min.
the alteration in corticosterone in rat blood as a 
response to an acute stressor was assessed on day 65 
of life. In the beginning of the experiment, a rat was 
placed into an immobilizing device; a blood sample 
(200 µl) was obtained from the tail after cutting off the 
tip. the animal was subjected to forced swim stress 
at 24°С for 10 min. ten min after the termination of 
the stressor exposure, the rat was repeatedly placed 
into the immobilizing device. the second blood sam-
ple was obtained; the animal was then placed back into 
its home cage. Sixty min after the termination of the 
forced swim stress, the rats were decapitated to obtain 
a blood sample. the sample was kept at 37°С for 20 min, 
and at 4°С for 60 min. the samples were then centri-
fuged (10 min, 5,000 rpm), and the serum was collected. 
the corticosterone level was subsequently assessed in 
the serum samples using the corticosterone eIA Kit 
designed to determine corticosterone in biological fluids 
(catalog № ADI-900-097, enzo).
RESULTS
Animals of both sexes were used in the experiments. 
the factor Sex had a considerable effect only on the 
body weight alteration of the rats. Other parameters 
did not differ significantly in either males or females. 
It was shown via use of the two-way AnOVA method 
(factor 1 –Group; factor 2 – Sex) for analyzing the al-
teration in the body weight of the rats during the first 
two months of life that the Group (F2,48 = 3.49, p < 0.04) 
and Sex factors (F1,48 = 34.91, p < 0.000001) had a sig-
nificant effect. However, no significant interaction be-
tween these factors was observed (F2,48 = 0.33, p = 0.72). 
no statistically significant differences in the influence 
of nI and Semax on animals of different sexes were re-
vealed by comparison with the results obtained for the 
male and female groups. this fact allows us to present 
the results obtained for the entire group of rats.
It was demonstrated that daily isolation during the 
first two weeks of life results in body weight decrease 
in 15-day-old rat pups (F2,229 = 39.60, p < 0.0001; Fig. 1A) 
and delay in eye-opening (F2,136 = 25.83, p < 0.0001; 
Fig. 1B) versus animals of the control group. In addi-
tion, a significant decrease in the blood glucose level 
was detected 1 day after the last nI in rats that had 
experienced neonatal stress in comparison with those 
in the control group (F2,107 = 9.53, p < 0.0001; Fig. 2). On 
day 15 of life, the pups subjected to nI were randomly 
divided into the nI and nI–Semax groups. the animals 
from these two groups had identical body weight, glu-
cose level at day 15 of life, and the age of eye-opening 
(Figs. 1, 2).
Half of the pups exposed to nI received a daily intra-
nasal Semax injection during the period from postnatal 
day 15 to day 28 (the nI–Semax group). the remaining 
animals (the nI group) and the animals from the control 
Body weight, g  Age of eye-opening, days
Control  NI  NI–Sem
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Fig. 1. Neonatal isolation effects on the body weight of 
rats at the age of 15 days (A) and on the time of eye-
opening (B). The number of animals in groups: 81/74/77. 
*** (p < 0.001) – significant difference from the control.
mmol/l
Control  NI  NI–Sem
15  30  48
8
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4
Fig. 2. Blood glucose level in rats. The x-axis – the age 
of animals (days); the y-axis – glucose concentration 
(mmol/l). The number of animals in groups: rats at the 
age of 15 days – 38/35/38; rats at the age of 30 and 48 
days – 12/11/11. **(p < 0.01) – significant difference 
from the control, #(p < 0.05) – significant difference from 
the NI group.reSeArcH ArtIcLeS
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group received distilled water. the lower body weight 
in rats from the nI and nI–Semax groups was observed 
during this period as compared to those in the control 
group (F2,84 = 27.75, p < 0.0001; Fig. 3A). no significant 
differences between the nI and nI–Semax groups 
were detected (F1,53 = 0.03, p > 0.85). the animals from 
the nI group had a lower body weight in comparison 
with that of the rats in the control group up to day 65 
of life (F1,25 = 4.63, p < 0.04). until day 48, the body 
weight of the rats in the nI–Semax group remained 
significantly lower than that in the control group. no 
significant differences were subsequently detected 
(F1,26 = 2.87, p > 0.10; Fig. 3B).
no significant differences in the blood glucose level 
in 30-day-old rats were revealed between the groups 
(F2,32 = 1.09, p > 0.25), although the blood glucose 
content in the pups from the nI group was lower as 
compared to the control values. Subsequent analysis 
demonstrated that the value of this parameter in the 
nI–Semax group was significantly higher than that 
in the nI group (p < 0.02 using the χ2 test). no differ-
ences in the glucose level were observed for the groups 
of 48-day-old rats (F2,31 = 0.74, p > 0.50) (Fig. 2).
the food motivation level of the animals was as-
sessed on day 42. In the rats from the nI group, the 
parameters characterizing the food motivation level 
were identical to those in the control group. the group 
of animals receiving Semax injections demonstrated 
a reduction of the latency to food intake, an increase 
in feeding duration and the amount of food con-
sumed during the experiment, as compared to these 
parameters in the control and nI groups (F2,31 > 3.3, 
p < 0.05) (Fig. 4). the aforementioned changes attest 
to increased food motivation in the nI–Semax ani-
mals. Hence, the neonatal isolation experience did not 
affect the food motivation level of rats; Semax admin-
istration to the rat pups exposed to nI resulted in an 
increase in food motivation.
It was demonstrated that the blood glucose level in 
nI rats after 24-h food deprivation was significantly 
lower as compared with that in the control and nI–
Semax groups (F2,31 = 3.32, p < 0.05). the glucose lev-
el after food deprivation in nI–Semax animals was 
identical to that in the control group. the repeated 
measurements (after the food intake) showed no sig-
nificant differences in this parameter between the 
groups (F2,31 = 0.46, p > 0.60) (Fig. 5). thus, neonatal 
isolation resulted in the reduction of the blood glucose 
level under conditions of food deprivation. Semax ad-
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Fig. 3. The growth rate of rats during the first (A) and the 
second (B) months of life. The x-axis – the age of animals 
(days), the y-axis – the body weight (g). The number of 
animals in groups: 32/29/28. *(p < 0.05), **(p < 0.01), 
and ***(p < 0.001) significant difference from the control.
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Fig. 4. The results of food motivation test for the rats 
at the age of 42 days. The rats were food-deprived for 
20 h before testing. The number of animals in groups: 
12/11/11. *(p < 0.05) – significant difference from the 
control, #(p < 0.05) – significant difference from the NI 
group.90 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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ministration eliminated the nI effect in case of this 
parameter.
the changes in the blood corticosterone level of the 
rats in response to a acute stressor were assessed at 
day 65 of life. the corticosterone basal level in nI rats 
was lower than that in the control group; however, this 
difference did not attain the level of statistical signifi-
cance (p > 0.05). ten minutes following stress termi-
nation, the blood corticosterone level in nI rats was 
significantly lower than that in the control and nI–
Semax groups (p < 0.05 using the χ2 test). no signifi-
cant differences between the groups with respect to 
this parameter were obtained 1 h after stress termina-
tion (Fig. 6). thus, neonatal isolation had resulted in a 
reduction in the stress-induced corticosterone release; 
whereas Semax administration had eliminated the iso-
lation effect, bringing the corticosterone level to the 
control value.
DISCUSSION
the rat pups were isolated from their mothers and lit-
termates for 5 h daily during the period from day 1 to 
day 14 of life. It was established earlier that rodents 
exhibit a weak response of the hypothalamic-pituitary-
adrenal system to moderate stress during the period of 
early neonatal development (the period known as pe-
riod of stress hyporeactivity). ensured by specific ma-
ternal behavior, the suppression of the stress response 
plays a significant role in the normal development of 
the nervous system. It was demonstrated that the isola-
tion of the pups from their mothers weakens the block-
age of the hypothalamic-pituitary-adrenal system [28, 
29]. nI procedure in the present work included daily 
food deprivation for 5 h, cold stress, and the absence of 
contact with the mother; so a combination of physical 
and emotional stress of high intensity was used. Fur-
thermore, as mentioned above, the separation of the rat 
pups from their mothers resulted in a weakening of the 
neonatal stress-hyporeactivity. thus, the actions used 
were stressors of high intensity. the model used can be 
considered to be a neonatal stress model.
It was demonstrated that chronic nI of rat pups 
during the period from day 1 to day 14 of life resulted 
in delayed eye-opening, which attests to the delayed 
physical development. the observed effects of nI are 
similar to those of MD [30, 31]. changes in body weight 
is another parameter characterizing the physical de-
velopment of the animals. In the model used, nI re-
sulted in delayed somatic growth of the rat pups. the 
differences between the body weight of the nI rats 
and the control rats remained during the entire ex-
periment time; i.e., at least up to the age of 2 months. 
there is a lack of consistency in the published data 
relating to the effect of MD on the body weight of the 
animals. In most of the studies, no changes in this pa-
rameter were detected [32, 33]. However, it was men-
mmol/l
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After feeding
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0 (basal level)  10  60
800
600
400
200
0
Control  NI  NI–Sem
Fig. 5. Blood glucose level in rats subjected to 20-hour 
food deprivation (before and after food consumption). 
The y-axis – glucose concentration (mmol/l). The number 
of animals in groups: 12/11/11. *(p < 0.05) – significant 
difference from the control, #(p < 0.05) – significant dif-
ference from the NI group.
Fig. 6. Stress-induced changes in corticosterone level: 
basal (0), 10 and 60 min after exposure to stress. The 
y-axis – serum corticosterone concentration (ng/ml). 
The number of animals in groups: 13/12/11. *(p < 0.05) 
– significant difference from the control, #(p < 0.05) – 
significant difference from the NI group.reSeArcH ArtIcLeS
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tioned in a number of studies that the pups that had 
undergone MD had a reduced body weight [19, 34, 35]. 
the difference in the effects can presumably be at-
tributed to the different conditions under which the 
pups were kept during the deprivation. thus, it was 
demonstrated that nI at a temperature of 30°С did not 
affect the body weight of the animals, whereas nI at 
22°С resulted in a decrease in body weight and growth 
deceleration [36]. In our experiments, during the nI 
procedure the pups were kept at 24–26°С. Presumably, 
a decrease in body temperature caused by the isolation 
of the pups from their mother and littermates plays a 
significant role in the development of the nI effects on 
their physical development. In addition, it was demon-
strated that maternal deprivation causes suppression 
of the cell response to three major trophic hormones 
(growth hormone, prolactin, and insulin). these chang-
es may result in somatic growth deceleration [37].
thus, the daily isolation during the first two weeks 
of life resulted in the deceleration of the physical de-
velopment of rat pups, which remained up to day 65 of 
life. Intranasal Semax injections to the 3- to 4-week-old 
rat pups weakened the effect of nI on the body weight 
of the animals; thus, these parameters approached the 
control level at days 55–65. this compensatory action of 
peptides on rat body weight is presumably based on the 
increased food motivation of the stressed animals that 
received Semax. In our case, the increased food motiva-
tion can be considered to be the adaptive response of 
the organism to the reduction in body weight caused as 
a result of neonatal isolation.
A significant decrease in the blood glucose level was 
recorded in rats that had experienced neonatal isolation 
at the age of 15 days. the glucose level was measured 
24 h after the last isolation procedure; i.e., by the time 
the blood sample was collected, the rat pups had been 
in contact with their mothers for 1 day. therefore, the 
decrease in the blood glucose level that was observed 
cannot be explained by food deprivation. the glucose 
level was not significantly different from the control 
values in the nI animals with unlimited access to food 
at the age of 30 and 48 days. However, under conditions 
of food deprivation, decreased glucose content was ob-
served in nI rats compared to that in the control group. 
the resulting data attest to the fact that neonatal iso-
lation causes long-lasting disturbances in metabolic 
processes in the rat organism. Semax administration 
to the animals exposed to nI resulted in an increase in 
the blood glucose level under conditions of both unlim-
ited access to food and food deprivation, attesting to the 
fact that the peptide has a normalizing effect. It is well-
known that it is necessary to maintain a physiological 
blood glucose level for the normal development of the 
brain in mammals. During the period when the nerv-
ous system is under development, hypoglycaemia may 
cause disorders both in cognitive functions and in the 
emotional status. these disorders do not disappear after 
the glucose level is normalized; they can manifest them-
selves in adulthood [38]. It was previously shown that 
nI during the first 1–2 weeks of life causes long-lasting 
behavioral changes: 1- to 2-month-old rats that had ex-
perienced nI demonstrated increased levels of anxiety 
and reduced exploratory activity. Subsequent Semax 
administration normalized the emotional state of the nI 
animals [27]. the abatement of nI-induced metabolic 
disturbances may have been one of the mechanisms of 
the positive effect of Semax on the emotional status of 
the animals that had experienced neonatal stress.
Study of the neonatal stress effect on the corticoster-
one level in blood demonstrated that nI had no effect 
on the basal level of this hormone; however, it resulted 
in a decrease in corticosterone release as a response 
to acute stress exposure. no effect of MD on the basal 
level of corticosterone had been observed in most of the 
previous studies [33, 39]. there has been no consistency 
in the published data relating to the effect of MD on 
stress-induced corticosterone release. It should be noted 
that most studies have been devoted to the investiga-
tion of the effects of maternal deprivation rather than 
neonatal isolation; this could account for the inconsist-
ency in the results. rees et al. [18] compared the effects 
of MD and nI and demonstrated that whereas MD did 
not affect the basal and stress-induced corticosterone 
release, nI resulted in a decrease in the stress-induced 
corticosterone release. the reduced hormonal response 
to stress in animals that had experienced neonatal iso-
lation may be caused by the exposure to repeated stress 
episodes, which may have led to the reiterated release 
of corticosterone. the repeated activation of the hy-
pothalamic-pituitary-adrenal system during the early 
neonatal period may result either in depletion of this 
system or in an increase in the efficiency of negative 
feedback [17, 35]. Semax administration to the rats sub-
jected to nI boosted the level of stress-induced corti-
costerone release to the control level. therefore, the 
subsequent administration of the peptide normalized 
the hormonal response to stress exposure, which had 
been disturbed by neonatal isolation.
It was previously demonstrated that daily neona-
tal isolation of white rat pups for 5 h during the pe-
riod from day 1 to day 14 of life results in long-lasting 
changes in animal behavior [27]. It has been shown in 
this study that the neonatal exposure to stress also re-
sults in delay of physical development in the animals, 
disturbance of metabolic processes, and weakening of 
the hormonal response to acute stress. these changes 
were observed during the first 1–2 months of life; i.e., 
they were of delayed and long-term character. the 92 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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negative effects of the neonatal stress were reduced by 
the chronic intranasal administration of Semax after 
the termination of the procedure of neonatal isolation. 
the results obtained can be used to broaden the range 
of clinical applications of Semax; in particular, for the 
treatment of pathologies in children during the early 
postnatal period.   
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